This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Drugs

Jim Cramer Explains Why Actavis Is the Healthcare Name to Own

Jim Cramer and Action Alerts PLUS Research Director Jack Mohr discuss why Actavis is severely undervalued and an extremely compelling healthcare investment at these levels.

04/18/15 - 09:00 AM EDT

Bioscrip, Alere, and Tetrapharmeuticals Top Health Holdings: Fund Manager

Gabelli Focus Five Fund Manager Dan Miller says BioScrip (BIOS), Alere (ALR), and Tetraphase Pharmaceuticals (TTPH) are his three top health care picks.

04/17/15 - 09:39 AM EDT

Try Jim Cramer's Action Alerts PLUS
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech

Biotech columnist Adam Feuerstein answers readers' questions about health care.

04/17/15 - 05:59 AM EDT

MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation

MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation

  • Tickers in this article:
  • MNOV

MedicNova (MNOV) shares are climbing after its drug received fast track status from the Food and Drug Administration.

04/16/15 - 02:21 PM EDT

Pacira Pharmaceuticals (PCRX) Stock Declines Today Following DOJ Subpoena

Pacira Pharmaceuticals (PCRX) Stock Declines Today Following DOJ Subpoena

  • Tickers in this article:
  • PCRX

Pacira Pharmaceuticals (PCRX) shares are falling after the Justice Department subpoenaed documents from the company concerning the advertisement for its Exparel pain reliever.

04/16/15 - 12:38 PM EDT

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Mylan's deal to buy Perrigo is taking another potential target off the block.

04/16/15 - 10:04 AM EDT

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

In which Musk learns how to put a happy spin on failure from biotech CEOs.

04/16/15 - 09:07 AM EDT

Foamix Pharmaceuticals (FOMX) Stock Spiked Following Pricing of Upsized Offering

Foamix Pharmaceuticals (FOMX) Stock Spiked Following Pricing of Upsized Offering

  • Tickers in this article:
  • FOMX

Foamix Pharmaceuticals (FOMX) shares closed up double digits after the company announced the pricing of its upsized public offering.

04/15/15 - 04:06 PM EDT

Teva, Actavis, Other Giants Set to Battle for Generics Space

Teva, Actavis, Other Giants Set to Battle for Generics Space

Teva, Actavis and other generics giants may start preying on each other.

04/15/15 - 11:30 AM EDT

Johnson & Johnson, Pfizer and Zimmer Holdings are Top Stock Picks

Johnson & Johnson, Pfizer and Zimmer Holdings are Top Stock Picks

Mark Spellman, portfolio manager at Alpine Equity Income Fund, says investors should come out on top by picking up shares of Johnson & Johnson, Pfizer and Zimmer Holdings.

04/14/15 - 04:16 PM EDT

Johnson & Johnson, Pfizer Good Stock Buys in Pricey Market

Johnson & Johnson, Pfizer Good Stock Buys in Pricey Market

Johnson & Johnson (JNJ) and Pfizer (PFE) are good stocks to own in a market that is currently overvalued.

04/14/15 - 11:58 AM EDT

Jim Cramer -- Buy GW Pharmaceuticals but Only on Pullback

Jim Cramer -- Buy GW Pharmaceuticals but Only on Pullback

  • Tickers in this article:
  • GWPH

TheStreet's Jim Cramer said GW Pharma is producing some important cannabis-based treatments but its stock should be considered a speculative buy.

04/14/15 - 11:50 AM EDT

Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts

Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts

The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.

04/14/15 - 09:46 AM EDT

Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO

Advaxis Shares Rise Ahead of Aduro's Rival Cancer Immunotherapy IPO

Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.

04/14/15 - 08:43 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs